The role of positron emission tomography imaging of β-amyloid in patients with Alzheimer's disease

Nuclear Medicine Communications

Volumn 31, Issue 1, 2010, Pages 4-11

  Xiong, Kun Lin ^a   Yang, Qing Wu ^a   Gong, Shui Gen ^a   Zhang, Wei Guo ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Amyloid; Diagnosis; Neuroimaging; Positron emission tomography; Therapy

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; BAY 949172; BF 227; CARBON 11; ENZYME INHIBITOR; FLUORODEOXYGLUCOSE F 18; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PITTSBURGH COMPOUND B; RADIOPHARMACEUTICAL AGENT; SB 13; SECRETASE INHIBITOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG STRUCTURE; FUNCTIONAL DISEASE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IN VIVO STUDY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; EARLY DIAGNOSIS; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROFIBRILLARY TANGLES; POSITRON-EMISSION TOMOGRAPHY;

EID: 74349089696     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32833019f3     Document Type: Review

References (76)

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60:1119-1122.
2. Wimo A, Jonsson L, Winblad B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 2006; 21:175-181.
3. Ziegler-Graham K, Brookmeyer R, Johnson E, Arrighi HM. Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers Dement 2008; 4:316-323.
4. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56:1133-1142.
5. Small GW, Bookheimer SY, Thompson PM, Cole GM, Huang SC, Kepe V, et al.. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol 2008; 7:161-172.
6. Tseng BP, Kitazawa M, LaFerla FM. Amyloid beta-peptide: the inside story. Curr Alzheimer Res 2004; 1:231-239.
7. Lim J, Lu KP. Pinning down phosphorylated tau and tauopathies. Biochim Biophys Acta 2005; 1739:311-322.
8. Goldman WP, Price JL, Storandt M, Grant EA, McKeel DW Jr, Rubin EH, et al.. Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology 2001; 56:361-367.
9. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81:741-766.
10. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256:184-185.
11. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297:353-356.
12. Jacobsen JS, Reinhart P, Pangalos MN. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. NeuroRx 2005; 2:612-626.
13. Hammoud DA, Hoffman JM, Pomper MG. Molecular neuroimaging: from conventional to emerging techniques. Radiology 2007; 245:21-42.
14. Thompson PW, Ye L, Morgenstern JL, Sue L, Beach TG, Judd DJ, et al.. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J Neurochem 2009; 109:623-630.
15. Ono M, Watanabe R, Kawashima H, Kawai T, Watanabe H, Haratake M, et al.. 18F-labeled flavones for in vivo imaging of beta-amyloid plaques in Alzheimer's brains. Bioorg Med Chem 2009; 17:2069-2076.
16. Nordberg A. The future: new methods of imaging exploration in Alzheimer's disease. Front Neurol Neurosci 2009; 24:47-53.
17. Lockhart A. Imaging Alzheimer's disease pathology: one target, many ligands. Drug Discov Today 2006; 11:1093-1099.
18. Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, et al.. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 2000; 343:450-456.
19. Backman L, Andersson JL, Nyberg L, Winblad B, Nordberg A, Almkvist O. Brain regions associated with episodic retrieval in normal aging and Alzheimer's disease. Neurology 1999; 52:1861-1870. (Pubitemid 29260901)
20. Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A 2004; 101:4637-4642.
21. Mathis CA, Klunk WE, Price JC, DeKosky ST. Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol 2005; 62:196-200.
22. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 2004; 3:519-527.
23. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, et al.. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 2001; 286:2120-2127.
24. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al.. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003; 30:1104-1113.
25. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al.. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006; 355:2652-2663.
26. Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology 2007; 69:871-877.
27. Cai L, Innis RB, Pike VW. Radioligand development for PET imaging of beta-amyloid (Abeta) - current status. Curr Med Chem 2007; 14:19-52.
28. Gibson RE, Burns HD, Hamill TG, Eng WS, Francis BE, Ryan C. Non-invasive radiotracer imaging as a tool for drug development. Curr Pharm Des 2000; 6:973-989.
29. Waterhouse RN. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 2003; 5:376-389.
30. Mathis CA,Wang Y, Klunk WE. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des 2004; 10:1469-1492.
31. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al.. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002; 10:24-35.
32. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al.. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55:306-319. (Pubitemid 38269583)
33. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, et al.. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 2004; 12:584-595.
34. Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M, et al.. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 2007; 48:553-561.
35. Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al.. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008; 7:129-135.
36. Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al.. Binding characteristics of radiofluorinated 6-dialkylamino-2- naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 2001; 21:RC189.
37. Agdeppa ED, Kepe V, Liu J, Small GW, Huang SC, Petric A, et al.. 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. Mol Imaging Biol 2003; 5:404-417.
38. Barrio JR, Kepe V, Satyamurthy N, Huang SC, Small G. Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment. J Nutr Health Aging 2008; 12:61S-65S.
39. Braskie MN, Klunder AD, Hayashi KM, Protas H, Kepe V, Miller KJ, et al.. Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease. Neurobiol Aging 2008; [Epub ahead of print].
40. Noda A, Murakami Y, Nishiyama S, Fukumoto D, Miyoshi S, Tsukada H, et al.. Amyloid imaging in aged and young macaques with [11C]PIB and [18F]FDDNP. Synapse 2008; 62:472-475.
41. Agdeppa ED, Kepe V, Petri A, Satyamurthy N, Liu J, Huang SC, et al.. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2- naphthyl]ethylidene) malono nitrile. Neuroscience 2003; 117:723-730.
42. Wang Y, Mathis CA, Huang GF, Debnath ML, Holt DP, Shao L, et al.. Effects of lipophilicity on the affinity and nonspecific binding of iodinated benzothiazole derivatives. J Mol Neurosci 2003; 20:255-260.
43. Mathis CA,Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003; 46:2740-2754.
44. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58:1791-1800.
45. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al.. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005; 25:1528-1547.
46. Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, et al.. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006; 60:145-147.
47. Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al.. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006; 67:1575-1580.
48. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al.. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006; 67:446-452.
49. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al.. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718-1725.
50. Koivunen J, Pirttila T, Kemppainen N, Aalto S, Herukka SK, Jauhianen AM, et al.. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008; 26:378-383.
51. Fripp J, Bourgeat P, Acosta O, Raniga P, Modat M, Pike KE, et al.. Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. Neuroimage 2008; 43:430-439.
52. Drzezga A, Grimmer T, Henriksen G, Stangier I, Perneczky R, Diehl-Schmid J, et al.. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage 2008; 39:619-633.
53. Mathis CA, Lopresti BJ, Klunk WE. Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol 2007; 34:809-822.
54. Grimmer T, Henriksen G,Wester HJ, Forstl H, Klunk WE, Mathis CA, et al.. Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol Aging 2008; [Epub ahead of print].
55. Mathis CA, Lopresti B, Mason N, Price J, Flatt N, Bi W, et al.. Comparison of the amyloid imaging agents [F-18]3'-F-PIB and [C-11]PIB in Alzheimer's disease and control subjects. J Nucl Med 2007; 48 (Suppl 2):56.
56. Rowe C, Ng S, Mulligan R, Ackermann U, Browne W, O'Keefe G, et al.. First results of a novel F-18 PET ligand for brain beta-amyloid imaging. J Nucl Med 2007; 48 (Suppl 2):57.
57. Ono M, Wilson A, Nobrega J, Westaway D, Verhoeff P, Zhuang ZP, et al.. 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl Med Biol 2003; 30:565-571.
58. Kung HF, Lee CW, Zhuang ZP, Kung MP, Hou C, Plossl K. Novel stilbenes as probes for amyloid plaques. J Am Chem Soc 2001; 123:12740-12741.
59. Ono M, Haratake M, Nakayama M, Kaneko Y, Kawabata K, Mori H, et al.. Synthesis and biological evaluation of (E)-3-styrylpyridine derivatives as amyloid imaging agents for Alzheimer's disease. Nucl Med Biol 2005; 32:329-335.
60. O'Keefe GJ, Saunder TH, Ng S, Ackerman U, Tochon-Danguy HJ, Chan JG, et al.. Radiation dosimetry of beta-amyloid tracers 11C-PIB and 18F-BAY94-9172. J Nucl Med 2009; 50:309-315.
61. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al.. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25:7709-7717.
62. Price JL, Morris JC. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Ann Neurol 1999; 45:358-368.
63. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, et al.. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007; 130:2837-2844.
64. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al.. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29:1456-1465.
65. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, et al.. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129:2856-2866.
66. Yaqub M, Tolboom N, Boellaard R, van Berckel BN, van Tilburg EW, Luurtsema G, et al.. Simplified parametric methods for [11C]PIB studies. Neuroimage 2008; 42:76-86.
67. Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology 2007; 69:1622-1634.
68. Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, et al.. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement 2008; 4:156-163.
69. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A 2001; 98:3334-3339.
70. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al.. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64:1553-1562.
71. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, et al.. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61:46-54.
72. Lahiri DK, Chen D, Maloney B, Holloway HW, Yu QS, Utsuki T, et al.. The experimental Alzheimer's disease drug posiphen [( +)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther 2007; 320:386-396.
73. Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, et al.. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol 2008; 63:621-631.
74. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al.. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005; 46:1959-1972.
75. Stokes MI, Trickey RJ. Screening for neurofibrillary tangles and argyrophilic plaques with Congo Red and polarized light. J Clin Pathol 1973; 26:241-242.
76. Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Shao L, et al.. The binding of 2-(40-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003; 23:2086-2092.